ES2133322T3 - Utilizacion de la proteina l2 para el tratamiento terapeutico de los tumores o lesiones causadas por el papilomavirus. - Google Patents

Utilizacion de la proteina l2 para el tratamiento terapeutico de los tumores o lesiones causadas por el papilomavirus.

Info

Publication number
ES2133322T3
ES2133322T3 ES92912857T ES92912857T ES2133322T3 ES 2133322 T3 ES2133322 T3 ES 2133322T3 ES 92912857 T ES92912857 T ES 92912857T ES 92912857 T ES92912857 T ES 92912857T ES 2133322 T3 ES2133322 T3 ES 2133322T3
Authority
ES
Spain
Prior art keywords
protein
papilomaviruses
tumors
therapeutic treatment
injuries caused
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92912857T
Other languages
English (en)
Inventor
William Fleming Hoggan Jarrett
Maria Saveria Campo
Kenneth Thomas Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Campaign Technology Ltd
Original Assignee
Cancer Research Campaign Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Campaign Technology Ltd filed Critical Cancer Research Campaign Technology Ltd
Application granted granted Critical
Publication of ES2133322T3 publication Critical patent/ES2133322T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Transceivers (AREA)
  • Mobile Radio Communication Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PROTEINA L2 DE VIRUS DE PAPILOMA (PARTICULARMENTE BPV-2 Y BPV-4) HA SIDO CLONADA COMO UNA PROTEINA DE FUSION CON BETA ENTOS. SE HA ENCONTRADO QUE LA VACUNACION DE TERNEROS TIENE TANTO EFECTOS PROFILACTICOS COMO PREVENCION DE TUMOR COMO UN EFECTO TERAPEUTICO EN REGRESION DE TUMOR.
ES92912857T 1991-06-26 1992-06-17 Utilizacion de la proteina l2 para el tratamiento terapeutico de los tumores o lesiones causadas por el papilomavirus. Expired - Lifetime ES2133322T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9113809A GB9113809D0 (en) 1991-06-26 1991-06-26 Papillomavirus l2 protein

Publications (1)

Publication Number Publication Date
ES2133322T3 true ES2133322T3 (es) 1999-09-16

Family

ID=10697369

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92912857T Expired - Lifetime ES2133322T3 (es) 1991-06-26 1992-06-17 Utilizacion de la proteina l2 para el tratamiento terapeutico de los tumores o lesiones causadas por el papilomavirus.

Country Status (12)

Country Link
US (2) US6380157B1 (es)
EP (1) EP0592480B1 (es)
JP (1) JP3533216B2 (es)
AT (1) ATE179458T1 (es)
AU (1) AU662910B2 (es)
DE (1) DE69229050T2 (es)
DK (1) DK0592480T3 (es)
ES (1) ES2133322T3 (es)
GB (1) GB9113809D0 (es)
GR (1) GR3030716T3 (es)
HK (1) HK1001309A1 (es)
WO (1) WO1993000436A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9207701D0 (en) * 1992-04-08 1992-05-27 Cancer Res Campaign Tech Papillomavirus e7 protein
US20020164350A1 (en) 1992-09-03 2002-11-07 Lowy Douglas R. Chimeric papillomavirus-like particles
US5618536A (en) * 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
AU719837B2 (en) * 1993-03-31 2000-05-18 Cancer Research Campaign Technology Limited Pharmaceuticals based on papillomaviruses
GB9306731D0 (en) * 1993-03-31 1993-05-26 Cancer Res Campaign Tech Vaccines
AUPM358894A0 (en) * 1994-01-31 1994-02-24 Csl Limited Modified papilloma virus l2 protein and vlps formed therefrom
GB9420146D0 (en) 1994-10-06 1994-11-23 Cancer Res Campaign Tech Papillomavirus vaccine
AU717647B2 (en) * 1994-10-06 2000-03-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Chimeric papillomavirus-like particles
AU717932B2 (en) * 1994-10-06 2000-04-06 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Chimeric papillomavirus-like particles
PT809700E (pt) * 1994-10-07 2006-09-29 Univ Loyola Chicago Particulas semelhantes ao papilomavirus e proteinas de fusao, assim como metodos para a sua producao
JP3958360B2 (ja) * 1995-02-24 2007-08-15 キャンタブ ファーマシューティカルズ リサーチ リミティド 免疫治療剤として役立つポリペプチド及びポリペプチド調製の方法
GB9505784D0 (en) * 1995-03-22 1995-05-10 Lynxvale Ltd Anti-tumour treatment
US7118754B1 (en) 1996-07-30 2006-10-10 Transgene S.A. Pharmaceutical composition for treating papillomavirus tumors and infection
AU781653B2 (en) * 1996-07-30 2005-06-02 Transgene S.A. Pharmaceutical composition for treating papollomavirus tumour and infection
FR2751879B1 (fr) * 1996-07-30 1998-10-30 Transgene Sa Composition pharmaceutique contre les tumeurs et infections a papillomavirus
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
FR2766091A1 (fr) * 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
US7494658B2 (en) 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
US7182947B2 (en) 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
CA2229955C (en) 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
US6926897B1 (en) 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
DE19905883C2 (de) * 1999-02-11 2001-05-23 Deutsches Krebsforsch Chimäre Virus-ähnliche Partikel bzw. chimäre Capsomere von BPV
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
KR20080075560A (ko) * 2000-06-26 2008-08-18 엔벤타 바이오파마슈티컬스 코포레이션 인간 파필로마 바이러스 치료법
DE60137230D1 (de) * 2000-07-06 2009-02-12 Univ Georgetown Stabile (fixierte) formen von viralen l1 capsidproteinen, deren fusionsproteinen, und deren verwendungen
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US20080160040A1 (en) * 2004-04-15 2008-07-03 Ghim Shin-Je Plant-produced compositions for treating papillomavirus infection and related methods
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
DE102008010954A1 (de) 2008-02-25 2009-08-27 Cichon, Günter, Prof.Dr. DNA-Vakzine zur Therapie und Prophylaxe von Gebärmutterhalskrebs und seinen prämalignen Vorstufen
JP5726727B2 (ja) 2008-05-26 2015-06-03 カディラ・ヘルスケア・リミテッド 麻疹−ヒトパピローマ混合ワクチン
KR20120059572A (ko) * 2009-08-26 2012-06-08 셀렉타 바이오사이언시즈, 인크. Ｔ－세포 도움을 유도하는 조성물
US9717783B2 (en) 2010-02-09 2017-08-01 Stc.Unm Immunogenic HPV L2-containing VLPs and related compositions, constructs, and therapeutic methods
US9533057B2 (en) 2010-02-09 2017-01-03 Stc.Unm Immunogenic HPV L2-containing VLPs and related compositions, constructs, and therapeutic methods
AU2013207962B2 (en) * 2012-01-12 2017-07-20 Unm Rainforest Innovations Immunogenic HPV L2-containing VLPs and related compositions and methods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0133123A1 (en) * 1983-07-25 1985-02-13 Mgi Pharma, Inc. Immunogens of papilloma viruses
US4777239A (en) 1986-07-10 1988-10-11 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic peptides of human papilloma virus
FR2632956B2 (fr) 1988-05-13 1991-07-12 Pasteur Institut Sondes a papillomavirus hpv49, hpv50, hpv54, hpv55; produits genetiquement et immunologiquement lies a ce papillomavirus hpv49, hpv50, hpv54, hpv55; procede de diagnostic in vitro d'infections a papillomavirus et d'immunisation in vivo contre ces papillomavirus

Also Published As

Publication number Publication date
AU662910B2 (en) 1995-09-21
EP0592480A1 (en) 1994-04-20
GB9113809D0 (en) 1991-08-14
JPH06508988A (ja) 1994-10-13
DE69229050D1 (de) 1999-06-02
EP0592480B1 (en) 1999-04-28
ATE179458T1 (de) 1999-05-15
JP3533216B2 (ja) 2004-05-31
GR3030716T3 (en) 1999-11-30
WO1993000436A1 (en) 1993-01-07
DK0592480T3 (da) 1999-11-08
HK1001309A1 (en) 1998-06-12
DE69229050T2 (de) 1999-10-21
US20020136736A1 (en) 2002-09-26
US6380157B1 (en) 2002-04-30
AU1985992A (en) 1993-01-25

Similar Documents

Publication Publication Date Title
ES2133322T3 (es) Utilizacion de la proteina l2 para el tratamiento terapeutico de los tumores o lesiones causadas por el papilomavirus.
IT8419266A1 (it) Dispositivo per generare calore in tessuti" del corpo umano e procedimento di cenerazione di calore, particolarmente per la cura di tumori
ES2172654T3 (es) Uso de nsaid para el tratamiento de carcinomas de celulas escamosas de la cavidad oral u orofaringe.
EP0909560A3 (en) Treatment o tumors with compounds having RXR retinoid receptor agoinst activity
DK0513702T3 (da) Melatoninderivater til anvendelse til behandling af søvnlidelser og til præ-anæstetisk medicinering
FR2657259B1 (es)
NO923953L (no) Peptider
MD413G2 (ro) Lampă de lumină polarizată pentru terapia de biostimulare
BR0115162A (pt) Tratamentos antitumorais eficazes
ATE120372T1 (de) Antikörper für die antilymphozyten- antikörpertherapie.
PT687184E (pt) Adenovirus recombinantes e sua utilizacao em terapia genica para o tratamento de patologias oculares
ES2185655T3 (es) Fracciones de acido aurintricarboxilico y analogos con actividad anti-angiogenica y metodos de uso.
AR223515A1 (es) Abrazadera nasal para el tratamiento profilactico o terapeutico de reses de ganado vacuno
DK0637306T3 (da) 4-Imidomethyl-1-[2'-phenyl-2'-oxoethyl]-piperidiner som serotonin-5HT2-antagonister, deres fremstilling og anvendelse til terapi
DE68904462D1 (de) 4-chinolincarbonsaeure-derivate, brauchbar zur behandlung von haut- und muco-epithelial-gewebekrankheiten.
ES2054718T3 (es) El uso de gepirona para la preparacion de una composicion farmaceutica para el tratamiento de la depresion atipica.
IT1116460B (it) Vaccino per enterotossina dell'escherichia coli per uso umano e veterinario
ES2128348T3 (es) Obtencion de composiciones para el tratamiento de alteraciones de la proliferacion celular.
DE69002946D1 (de) Paracetamol enthaltende arzneizubereitung.
ES545155A0 (es) Procedimiento para la obtencion de (pirrol-1-il)-fenil-dihi-dropiridazinona
MX164619B (es) Composicion para el tratamiento de lesiones cutaneas
DE3861494D1 (de) Pharmazeutische zusammensetzung zur behandlung von tumoren.
ZA849576B (en) 1,7-diphenyl-3-methyllaza-7-cyano-8-methylnonane for use in the treatment of diseases
ITMI930341A1 (it) Impiego terapeutico del pirrolidon carbossilato di piridossina
SE8008959L (sv) Ultraviolettemitterande ce-jordalkalimetall-aluminat-lysemne och lampor med dylikt

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 592480

Country of ref document: ES